Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: Factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2

Toxicology Mechanisms and Methods

Volumn 23, Issue 1, 2013, Pages 48-56

  Kolnagou, Annita ^a   Natsiopoulos, Konstantinos ^a   Kleanthous, Marios ^a   Ioannou, Alexia ^a   Kontoghiorghes, George J ^a  

^a Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

Cardiac; Chelation therapy with deferiprone and deferoxamine; Heterogenic iron distribution; Liver; MRI T2; Pancreatic iron; Serum ferritin; Spleen; Thalassemia iron overload

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON; SYMPHONY SYNGO MR 1.5 TESLA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BETA THALASSEMIA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; FERRITIN BLOOD LEVEL; HEART; HUMAN; IRON CHELATION; IRON STORAGE; LIVER; LIVER LEVEL; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PANCREAS; PATIENT MONITORING; PRIORITY JOURNAL; SPLEEN;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BODY BURDEN; CHILD; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIUM; PANCRELIPASE; PYRIDONES; SPLEEN; YOUNG ADULT;

EID: 84871416108     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2012.727198     Document Type: Article

References (47)

1. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ. 2001. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22:2171-2179. (Pubitemid 33139463)
2. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Pennell DJ. 2004. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 127:348-355. (Pubitemid 39468951)
3. Anderson LJ, Westwood MA, Prescott E, Walker JM, Pennell DJ, Wonke B. 2006. Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol 115:106-108. (Pubitemid 43130442)
4. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. 2002. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet 360:516-520. (Pubitemid 35232104)
5. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, Galimberti M, Polchi P, Lucarelli G. 2000. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 343:327-331. (Pubitemid 30616698)
6. Au WY, Lam WW, Chu W, Tam S, Wong WK, Liang R, Ha SY. 2008. A T2* magnetic resonance imaging study of pancreatic iron overload in thalassemia major. Haematologica 93:116-119. (Pubitemid 351156159)
7. Boddaert N, Le Quan Sang KH, Rötig A, Leroy-Willig A, Gallet S, Brunelle F, Sidi D, Thalabard JC, Munnich A, Cabantchik ZI. 2007. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110:401-408. (Pubitemid 47026862)
8. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, Sabato V, Melevendi C, Cappellini MD, Verlato G. 1998. Survival and disease complications in thalassemia major. Ann NY Acad Sci 850:227-231. (Pubitemid 28369763)
9. Brewer CJ, Coates TD, Wood JC. 2009. Spleen R2 and R2* in ironoverloaded patients with sickle cell disease and thalassemia major. J Magn Reson Imaging 29:357-364.
10. Damianou CH, Koutras M. 1998. Introduction to statistics. Part (II). Athens, Greece: Symmetria Edition.
11. Drakonaki EE, Maris TG, Papadakis A, Karantanas AH. 2007. Bone marrow changes in β-thalassemia major: quantitative MR imaging findings and correlation with iron stores. Eur Radiol 17:2079-2087. (Pubitemid 47097466)
12. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. 2010. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 148:466-475.
13. Fischer R, Harmatz PR. (2009). Non-invasive assessment of tissue iron overload. Hematology Am Soc Hematol Educ Program 2009: 215-221.
14. Forni GL, Balocco M, Cremonesi L, Abbruzzese G, Parodi RC, Marchese R. 2008. Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov Disord 23:904-907.
15. Inati A, Musallam KM, Wood JC, Sheikh-Taha M, Daou L, Taher AT. 2009. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease. Eur J Haematol 83:565-571.
16. Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ. 2006. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. Hemoglobin 30:219-227. (Pubitemid 43977324)
17. Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ. 2008a. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin 32:41-47. (Pubitemid 351264511)
18. Kolnagou A, Fessas C, Papatryphonas A, Economides C, Kontoghiorghes GJ. 2004. Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia. Br J Haematol 127:360-1; author reply 361.
19. Kolnagou A, Kleanthous M, Kontoghiorghes GJ. 2010. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/ deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. Eur J Haematol 85:430-438.
20. Kolnagou A, Kleanthous M, Kontoghiorghes GJ. 2011. Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy. Hemoglobin 35:186-198.
21. Kolnagou A, Kontoghiorghes GJ. 2006. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Hemoglobin 30:239-249. (Pubitemid 43977326)
22. Kolnagou A, Kontoghiorghes GJ. 2010. New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores. Br J Haematol 150:489-90; author reply 491.
23. Kolnagou A, Michaelides Y, Kontos C, Kyriacou K, Kontoghiorghes GJ. 2008b. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone. Hemoglobin 32:17-28. (Pubitemid 351264514)
24. Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ. 2009. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol. Hemoglobin 33:312-322.
25. Kontoghiorghes GJ, Eracleous E, Economides C, Kolnagou A. 2005. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations. Curr Med Chem 12:2663-2681. (Pubitemid 41601566)
26. Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L. 1990. Pharmacokinetic studies in humans with the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one. Clin Pharmacol Ther 48:255-261. (Pubitemid 20323651)
27. Kontoghiorghes GJ, Kolnagou A. 2003. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 361:184.
28. Kontoghiorghes GJ, Kolnagou A. 2005. Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators. Curr Med Chem 12:2695-2709. (Pubitemid 41601568)
29. Kontoghiorghes GJ. 2006. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. Hemoglobin 30:183-200.
30. Kontoghiorghes GJ. 2009. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients. Hemoglobin 33:332-338.
31. Kwiatkowski JL. 2011. Management of transfusional iron overload-differential properties and efficacy of iron chelating agents. J Blood Med 2:135-149.
32. Marsella M, Pepe A, Borgna-Pignatti C. 2010. Better survival and less cardiac morbidity in female patients with thalassemia major: a review of the literature. Ann N Y Acad Sci 1202:129-133.
33. Mavrogeni SI, Gotsis ED, Markussis V, Tsekos N, Politis C, Vretou E, Kermastinos D. 1998. T2 relaxation time study of iron overload in b-thalassemia. MAGMA 6:7-12. (Pubitemid 28500263)
34. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. 2008. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 10:42.
35. Ooi GC, Khong PL, Chan GC, Chan KN, Chan KL, Lam W, Ng I, Ha SY. 2004. Magnetic resonance screening of iron status in transfusiondependent β-thalassaemia patients. Br J Haematol 124:385-390. (Pubitemid 38167991)
36. Papakonstantinou O, Alexopoulou E, Economopoulos N, Benekos O, Kattamis A, Kostaridou S, Ladis V, Efstathopoulos E, Gouliamos A, Kelekis NL. 2009. Assessment of iron distribution between liver, spleen, pancreas, bone marrow, and myocardium by means of R2 relaxometry with MRI in patients with β-thalassemia major. J Magn Reson Imaging 29:853-859.
37. Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, Putti MC, Lippi A, Romeo MA, Bisconte MG, Filosa A, Caruso V, Quarta A, Pitrolo L, Missere M, Midiri M, Rossi G, Positano V, Lombardi M, Maggio A. 2011. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica 96:41-47.
38. Prus E, Fibach E. 2011. Uptake of non-transferrin iron by erythroid cells. Anemia 2011:945289.
39. Rajapurkar MM, Alam MG, Bhattacharya A, Shah S. 2007a. Novel treatment for diabetic nephropathy. J Am Soc Nephrol 18:329A.
40. Rajapurkar MM, Beliga R, Shah S. 2007b. Treatment of patients with glomerulonephritis with an oral iron chelator. J Am Soc Nephrol 18:57A-58A.
41. Roghi A, Cappellini MD, Wood JC, Musallam KM, Patrizia P, Fasulo MR, Cesaretti C, Taher AT. 2010. Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. Ann Hematol 89:585-589.
42. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ. 2007. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115:1876-1884. (Pubitemid 46598901)
43. Tefler P, Goen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, Pavlides N, Psiloines M, Simamonian K, Skordos G, Sitarou M, Angastiniotis M. 2006. Survival of medically treated Thalassaemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica 91:1187-1192. (Pubitemid 44408428)
44. Wood JC, Ghugre N. 2008. Magnetic resonance imaging assessment of excess iron in thalassemia, sickle cell disease and other iron overload diseases. Hemoglobin 32:85-96. (Pubitemid 351264532)
45. Wood JC, Kang BP, Thompson A, Giardina P, Harmatz P, Glynos T, Paley C, Coates TD. 2010. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 116:537-543.
46. Wu KH, Chang JG, Ho YJ, Wu SF, Peng CT. 2006. Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with β-thalassemia major. Hemoglobin 30:251-256.
47. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S. 1989. Survival and causes of death in Thalassaemia major. Lancet 2:27-30. (Pubitemid 19158169)